Bile Acids in Inflammatory Bowel Disease: From Pathophysiology to Treatment

Samantha H. Bai; Arun Chandnani; Siyan Cao

doi:10.3390/biomedicines12122910

Bile Acids in Inflammatory Bowel Disease: From Pathophysiology to Treatment

Samantha H. Bai, Arun Chandnani, Siyan Cao

Research output: Contribution to journal › Review article › peer-review

2 Scopus citations

Abstract

Inflammatory bowel disease (IBD) is a chronic condition that affects about 7 million people worldwide, and new therapies are needed. Understanding the complex roles that bile acids (BAs) play in IBD may lead to the development of novel IBD treatments independent of direct immunosuppression. This review discusses the latest discoveries in the roles BAs play in IBD pathogenesis and explores how these discoveries offer promising new therapeutic targets to treat IBD and improve patient outcomes. Several therapies discussed include specific BA receptor (BAR) agonists, dietary therapies, supplements, probiotics, and mesenchymal stem cell therapies that have all been shown to decrease IBD disease activity.

Original language	English
Article number	2910
Journal	Biomedicines
Volume	12
Issue number	12
DOIs	https://doi.org/10.3390/biomedicines12122910
State	Published - Dec 2024

Keywords

bile acids
Crohn’s disease
inflammatory bowel disease
new therapies
pathogenesis
ulcerative colitis

Access to Document

10.3390/biomedicines12122910

Cite this

@article{845da482eab94ec6a914b76a3dfc63f1,

title = "Bile Acids in Inflammatory Bowel Disease: From Pathophysiology to Treatment",

abstract = "Inflammatory bowel disease (IBD) is a chronic condition that affects about 7 million people worldwide, and new therapies are needed. Understanding the complex roles that bile acids (BAs) play in IBD may lead to the development of novel IBD treatments independent of direct immunosuppression. This review discusses the latest discoveries in the roles BAs play in IBD pathogenesis and explores how these discoveries offer promising new therapeutic targets to treat IBD and improve patient outcomes. Several therapies discussed include specific BA receptor (BAR) agonists, dietary therapies, supplements, probiotics, and mesenchymal stem cell therapies that have all been shown to decrease IBD disease activity.",

keywords = "bile acids, Crohn{\textquoteright}s disease, inflammatory bowel disease, new therapies, pathogenesis, ulcerative colitis",

author = "Bai, {Samantha H.} and Arun Chandnani and Siyan Cao",

note = "Publisher Copyright: {\textcopyright} 2024 by the authors.",

year = "2024",

month = dec,

doi = "10.3390/biomedicines12122910",

language = "English",

volume = "12",

journal = "Biomedicines",

issn = "2227-9059",

number = "12",

}

TY - JOUR

T1 - Bile Acids in Inflammatory Bowel Disease

T2 - From Pathophysiology to Treatment

AU - Bai, Samantha H.

AU - Chandnani, Arun

AU - Cao, Siyan

PY - 2024/12

Y1 - 2024/12

N2 - Inflammatory bowel disease (IBD) is a chronic condition that affects about 7 million people worldwide, and new therapies are needed. Understanding the complex roles that bile acids (BAs) play in IBD may lead to the development of novel IBD treatments independent of direct immunosuppression. This review discusses the latest discoveries in the roles BAs play in IBD pathogenesis and explores how these discoveries offer promising new therapeutic targets to treat IBD and improve patient outcomes. Several therapies discussed include specific BA receptor (BAR) agonists, dietary therapies, supplements, probiotics, and mesenchymal stem cell therapies that have all been shown to decrease IBD disease activity.

AB - Inflammatory bowel disease (IBD) is a chronic condition that affects about 7 million people worldwide, and new therapies are needed. Understanding the complex roles that bile acids (BAs) play in IBD may lead to the development of novel IBD treatments independent of direct immunosuppression. This review discusses the latest discoveries in the roles BAs play in IBD pathogenesis and explores how these discoveries offer promising new therapeutic targets to treat IBD and improve patient outcomes. Several therapies discussed include specific BA receptor (BAR) agonists, dietary therapies, supplements, probiotics, and mesenchymal stem cell therapies that have all been shown to decrease IBD disease activity.

KW - bile acids

KW - Crohn’s disease

KW - inflammatory bowel disease

KW - new therapies

KW - pathogenesis

KW - ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=85213222424&partnerID=8YFLogxK

U2 - 10.3390/biomedicines12122910

DO - 10.3390/biomedicines12122910

M3 - Review article

C2 - 39767816

AN - SCOPUS:85213222424

SN - 2227-9059

VL - 12

JO - Biomedicines

JF - Biomedicines

IS - 12

M1 - 2910

ER -

Bile Acids in Inflammatory Bowel Disease: From Pathophysiology to Treatment

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this